Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 7/20 | 0.64 |
| ▸ | FBP1 | P09467 | 2/20 | 0.51 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.40 |
| ▸ | UMPS | P11172 | 1/20 | 0.35 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.35 |
| ▸ | ATIC | P31939 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15756287 | 1.00 | IGF2R (0.64) | IGF2RFBP1AMDHD2UMPSDNPH1 | |
| SCHEMBL16022926 | 0.89 | IGF2R (0.63) | IGF2RFBP1AMDHD2UMPSATIC | |
| SCHEMBL12633587 | 0.89 | IGF2R (0.63) | IGF2RFBP1AMDHD2UMPSATIC | |
| SCHEMBL16022907 | 0.89 | IGF2R (0.63) | IGF2RFBP1AMDHD2UMPSATIC | |
| SCHEMBL19509824 | 0.86 | IGF2R (0.78) | IGF2RFBP1AMDHD2 | |
| SCHEMBL19500443 | 0.86 | IGF2R (0.78) | IGF2RFBP1AMDHD2 | |
| SCHEMBL19509827 | 0.86 | IGF2R (0.78) | IGF2RFBP1AMDHD2 | |
| SCHEMBL21470011 | 0.85 | IGF2R (0.67) | IGF2RFBP1AMDHD2UMPSDNPH1 | |
| SCHEMBL19929291 | 0.85 | IGF2R (0.67) | IGF2RFBP1AMDHD2UMPS | |
| SCHEMBL6230811 | 0.85 | IGF2R (0.67) | IGF2RFBP1AMDHD2UMPSDNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256017-A1 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF | PROTALIX LTD. (IL) | 2014-09-11 | — | — | US | disclosed |
| US-8742079-B2 | Saccharide-containing protein conjugates and uses thereof | PROTALIX LTD. (IL) | 2014-06-03 | — | — | US | disclosed |
| US-20110105379-A1 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF | PROTALIX LTD. (IL) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256017-A1 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF | STT3B, STT3A, DDOST | IGF2R 295/4885FBP1 527/4885AMDHD2 122/4885 |
| US-20110105379-A1 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF | STT3B, STT3A, DDOST | IGF2R 295/4885FBP1 527/4885AMDHD2 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.